184 related articles for article (PubMed ID: 891391)
21. Pathogenesis and clinical management of hyperuricemia and gout.
Mangini RJ
J Maine Med Assoc; 1979 Mar; 70(3):118-20, 122-7. PubMed ID: 374661
[No Abstract] [Full Text] [Related]
22. [Clinical studies on hyperuricemia and gout after transplantation].
Imanishi M; Ikegami M; Ishii T; Nishioka T; Uemura T; Kunikata S; Kanda H; Matsuura T; Akiyama T; Kurita T
Hinyokika Kiyo; 1990 Aug; 36(8):893-6. PubMed ID: 2239590
[TBL] [Abstract][Full Text] [Related]
23. [Treatment of hyperuricemia and gout].
Gröbner W; Walter-Sack I
Med Monatsschr Pharm; 2005 May; 28(5):159-64; quiz 165-6. PubMed ID: 15912988
[No Abstract] [Full Text] [Related]
24. [The use of Allomaron in treating hyperuricemia].
Balkarov IM
Ter Arkh; 1994; 66(1):40-2. PubMed ID: 8146793
[No Abstract] [Full Text] [Related]
25. Understanding hyperuricemia: nursing implications.
Johnson ES
Nurs Clin North Am; 1972 Jun; 7(2):399-406. PubMed ID: 4482424
[No Abstract] [Full Text] [Related]
26. [Preliminary clinical experiences with mercapto-pyrazolo-pyrimidine (thiopurinol) in the therapy of gout].
Solazzi F; Cirla E; Tosi S
Reumatismo; 1971; 23(5):257-63. PubMed ID: 5164647
[No Abstract] [Full Text] [Related]
27. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
[TBL] [Abstract][Full Text] [Related]
28. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout.
Perez-Ruiz F; Hernandez-Baldizon S; Herrero-Beites AM; Gonzalez-Gay MA
Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1299-305. PubMed ID: 20506124
[TBL] [Abstract][Full Text] [Related]
29. [Management of hyperuricemia in diabetes].
Hirai A; Saito Y
Nihon Rinsho; 1997 Nov; 55 Suppl():781-5. PubMed ID: 9434564
[No Abstract] [Full Text] [Related]
30. [Therapeutic agents for gout effecting the kidney].
Ueda Y; Kono H; Kobayashi Y; Kagawa K; Yonezawa H
Geka Chiryo; 1970 Mar; 22(3):317-22. PubMed ID: 5467650
[No Abstract] [Full Text] [Related]
31. [Allomaron in hyperuricemia and gout].
Barsom S
ZFA (Stuttgart); 1979 Aug; 55(24):1336-40. PubMed ID: 539082
[No Abstract] [Full Text] [Related]
32. [Gout: physiopathology, diagnosis, course, treatment].
Chazerain P; Ziza JM
Rev Prat; 1998 Sep; 48(13):1453-6. PubMed ID: 10050628
[No Abstract] [Full Text] [Related]
33. Management of gout and hyperuricemia.
Wisner DE; Simkin PA
Prim Care; 1984 Jun; 11(2):283-94. PubMed ID: 6206519
[TBL] [Abstract][Full Text] [Related]
34. Hyperuricemia and gout: an update.
Khachadurian AK
Am Fam Physician; 1981 Dec; 24(6):143-8. PubMed ID: 6895439
[TBL] [Abstract][Full Text] [Related]
35. Treatment of gout with alternate-day hypo-uricaemic drugs.
Nishizawa T; Nishida Y; Masuda T; Akaoka I
Rheumatol Rehabil; 1978 Aug; 17(3):143-9. PubMed ID: 705170
[No Abstract] [Full Text] [Related]
36. The physiologic approach to hyperuricemia.
Rastegar A; Thier SO
N Engl J Med; 1972 Mar; 286(9):470-6. PubMed ID: 4550616
[No Abstract] [Full Text] [Related]
37. [Hyperuricemia and benziodarone].
Haddad N; Zamouri A; Naccache S
Tunis Med; 1973; 51(2):103-4. PubMed ID: 4784400
[No Abstract] [Full Text] [Related]
38. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout.
van Lieshout-Zuidema MF; Breedveld FC
J Rheumatol; 1993 Aug; 20(8):1383-5. PubMed ID: 8230024
[TBL] [Abstract][Full Text] [Related]
39. Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study.
Lin HC; Daimon M; Wang CH; Ho Y; Uang YS; Chiang SJ; Wang LH
Int J Cardiol; 2017 Apr; 233():85-90. PubMed ID: 28202260
[TBL] [Abstract][Full Text] [Related]
40. [Uninterrupted therapy of hyperuricemia and gout].
Schilling F
Reumatizam; 1971; 18(3):79-82. PubMed ID: 5097291
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
